SenesTech, Inc. (SNES) · Oct 22, 2026 · Delisting
Nasdaq deficiency — Below $1.00 bid price for 30 days; cure period ends April 19, 2027
SenesTech’s Nasdaq listing warning raises dilution and delisting risk, even as preliminary Q3 revenue beats the limited published estimate.
SenesTech is trying to turn its rodent-fertility products into a commercial business: Evolve-led e-commerce is growing quickly, while the company is still building a professional B2B sales channel and remains dependent on outside capital. Q2 filings showed Evolve generating most revenue and e-commerce driving growth, but the company’s 2025 annual report still described commercialization, market acceptance and working-capital funding as core unresolved requirements.
| Metric | Filing / reference |
|---|---|
| Preliminary Q3 2026 revenue | ~$1.1 million (Company press release) |
| Sequential growth | 40% (Company press release) |
| Year-over-year growth | 55% (Company press release) |
| Published Q3 revenue estimate | ~$0.80 million (external estimate) |
The business momentum is real, and the preliminary revenue figure appears better than the limited published expectation. Management said Q3 revenue was the company’s highest ever, up 40% sequentially and 55% year over year. That supports the e-commerce-led commercialization story, but it is still revenue growth from a very small base—not evidence yet that the company has solved its losses or funding needs.
The immediate new development is a listing problem, not an operating setback. Nasdaq says the stock failed to maintain the $1.00 minimum bid price for 30 consecutive business days; trading continues for now, with 180 calendar days to cure the deficiency. This adds a separate execution deadline to an already fragile commercial transition.
The filing makes financing risk more prominent because the cure may require a capital action. SenesTech says it is evaluating financing requirements and alternatives while balancing liquidity against dilution. 〔0〕 A reverse split or other share-price remedy is not announced, but the combination of sub-$1 trading, limited scale and explicit financing language leaves shareholders exposed to potential dilution or a more difficult funding process.
Glenbrook’s involvement is potentially supportive but not yet a solution. The holder reports 38% ownership and says it will work with the board and management, but the filing gives no binding financing, restructuring or operating commitment. 〔1〕
Bottom line: The filing contains a genuine operating bright spot, but the new Nasdaq deficiency makes the capital and listing overhang more important than the revenue beat. The business is progressing, yet the company still has to turn that growth into enough scale and financial stability to avoid a forced remedy by April 19, 2027.
Q3 results, expected November 9
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!